Evercore ISI analyst Gavin Clark-Gartner downgraded Rocket Pharmaceuticals (RCKT) to In Line from Outperform with a $5 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank
- Broadcom, Arista Networks initiated: Wall Street’s top analyst calls
- Goldman downgrades Rocket to Sell on ‘surprising and concerning’ update
- Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue